Literature DB >> 29536377

OCT4 but not SOX2 expression correlates with worse prognosis in surgical patients with triple-negative breast cancer.

Jia-Ming Zhang1, Kai Wei2, Ming Jiang3.   

Abstract

BACKGROUND: Octamer-binding transcription factor 4 (OCT4) and SRY (sex determining region Y)-box 2 (SOX2) are common biomarkers of cancer stem cells, which contribute to the pathological processes of several carcinomas, while little is known about the effects of OCT4 and SOX2 on the prognosis of triple-negative breast cancer (TNBC). The purpose was to evaluate the correlation of tumor tissue OCT4 and SOX2 expressions with clinicopathological features and overall survival (OS) in surgical TNBC patients.
METHODS: 127 surgical patients with TNBC were enrolled in this cohort study. Tumor tissue samples were obtained during the operation. OCT4 and SOX2 expressions were assessed by immunofluorescent staining.
RESULTS: 32 (25%) TNBC patients with OCT4 positive expression (OCT4+), 21 (17%) patients with SOX2 positive expression (SOX2+), and 11 (9%) patients with both OCT4+ and SOX2+ were observed. OCT4 expression was positively associated with histologic grade (P < 0.001), pathological tumor size (P = 0.014), N stage (P < 0.001) and TNM stage (P < 0.001), while SOX2 expression was positively correlated with histologic grade (P < 0.001), pathological tumor size (P = 0.033) and Ki-67 expression (P = 0.016). Kaplan-Meier (K-M) curves suggested OCT4+ was correlated with shorter OS compared with OCT4- (P < 0.001), while no correlation between SOX2+ with OS in all patients (P = 0.128) was observed. Multivariate Cox model indicated that OCT4+ (P < 0.001) were independent factors for worse OS.
CONCLUSIONS: Tumor tissue OCT4 but not SOX2 expression was positively correlated with histologic grade, pathological tumor size, N stage and TNM stage, and it could be served as an independent biomarker to predict worse prognosis in surgical patients with TNBC.

Entities:  

Keywords:  OCT4; Prognosis; SOX2; Triple-negative breast cancer; Tumor tissue

Mesh:

Substances:

Year:  2018        PMID: 29536377     DOI: 10.1007/s12282-018-0844-x

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  19 in total

1.  Inhibition of Wnt signaling by Frizzled7 antibody-coated nanoshells sensitizes triple-negative breast cancer cells to the autophagy regulator chloroquine.

Authors:  Jianxin Wang; Megan N Dang; Emily S Day
Journal:  Nano Res       Date:  2020-04-25       Impact factor: 8.897

2.  Overexpression of SMC4 predicts a poor prognosis in cervical cancer and facilitates cancer cell malignancy phenotype by activating NF-κB pathway.

Authors:  Hui He; Cui Zheng; Yunxian Tang
Journal:  Hum Cell       Date:  2021-09-03       Impact factor: 4.174

Review 3.  The Clinical and Molecular Characteristics of Sex-Determining Region Y-Box 2 and its Prognostic Value in Breast Cancer: A Systematic Meta-Analysis.

Authors:  Gang Zhao; Xiaozhen Wang; Limei Qu; Zhu Zhu; Jinghui Hong; Haiqin Hou; Zuonong Li; Jun Wang; Zheng Lv
Journal:  Breast Care (Basel)       Date:  2020-03-26       Impact factor: 2.860

4.  FOXM1 mediates GDF-15 dependent stemness and intrinsic drug resistance in breast cancer.

Authors:  Anupama Modi; Purvi Purohit; Dipayan Roy; Jeewan Ram Vishnoi; Puneet Pareek; Poonam Elhence; Priyanka Singh; Shailja Sharma; Praveen Sharma; Sanjeev Misra
Journal:  Mol Biol Rep       Date:  2022-01-23       Impact factor: 2.316

5.  CONFIGURE: A pipeline for identifying context specific regulatory modules from gene expression data and its application to breast cancer.

Authors:  Sungjoon Park; Doyeong Hwang; Yoon Sun Yeo; Hyunggee Kim; Jaewoo Kang
Journal:  BMC Med Genomics       Date:  2019-07-11       Impact factor: 3.063

6.  OCT4, SOX2, and NANOG positive expression correlates with poor differentiation, advanced disease stages, and worse overall survival in HER2+ breast cancer patients.

Authors:  Fan Yang; Jiaming Zhang; Hua Yang
Journal:  Onco Targets Ther       Date:  2018-11-06       Impact factor: 4.147

Review 7.  Novel and Alternative Targets Against Breast Cancer Stemness to Combat Chemoresistance.

Authors:  Sangita Sridharan; Cory M Howard; Augustus M C Tilley; Boopathi Subramaniyan; Amit K Tiwari; Randall J Ruch; Dayanidhi Raman
Journal:  Front Oncol       Date:  2019-10-16       Impact factor: 6.244

8.  Targeting of the Eukaryotic Translation Initiation Factor 4A Against Breast Cancer Stemness.

Authors:  Sangita Sridharan; Megan Robeson; Diwakar Bastihalli-Tukaramrao; Cory M Howard; Boopathi Subramaniyan; Augustus M C Tilley; Amit K Tiwari; Dayanidhi Raman
Journal:  Front Oncol       Date:  2019-12-06       Impact factor: 6.244

9.  Diagnostic significance and carcinogenic mechanism of pan-cancer gene POU5F1 in liver hepatocellular carcinoma.

Authors:  Dingdong He; Xiaokang Zhang; Jiancheng Tu
Journal:  Cancer Med       Date:  2020-09-26       Impact factor: 4.452

10.  The role of SOX2 overexpression in prognosis of patients with solid tumors: A meta-analysis and system review.

Authors:  Shengjie Wang; Xinli Liu; Ying Chen; Xiaozhen Zhan; Tujin Wu; Bing Chen; Guangwen Sun; Songling Yan; Lin Xu
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.